Turkiye Klinikleri Journal of Dental Sciences

.: REVIEW
İlaç Kullanımına Bağlı Gelişen Çene Osteonekrozu: Tanımı, Önlenmesi, Tedavisi ve Güncel Yaklaşımlar
Medication Related Osteonecrosis of the Jaws: Definition, Prevention, Treatment and Current Approaches
Damla SİVRİa, Sibel ÇEBİ ATAKa, Sedat ÇETİNERa, Kübra ÖZTÜRKb , Begüm OKURc
aGazi Üniversitesi Diş Hekimliği Fakültesi, Ağız, Diş ve Çene Cerrahisi ABD, Ankara, TÜRKİYE
bNuh Naci Yazgan Üniversitesi Diş Hekimliği Fakültesi, Ağız, Diş ve Çene Cerrahisi ABD, Kayseri, TÜRKİYE
cÖzel Dentgroup Diş Kliniği, Ankara, TÜRKİYE
Turkiye Klinikleri J Dental Sci. 2020;26(3):462-71
doi: 10.5336/dentalsci.2019-72332
Article Language: TR
Full Text
ÖZET
 İlaç kullanımına bağlı gelişen çene osteonekrozu [medication related osteonecrosis of the jaw (MRONJ)] hakkında ilk makale 2003 yılında yayımlandı. MRONJ, kemik metastazı veya osteoporoz için antirezorptif veya antianjiyojenik ilaç alan hastalarda 8 haftadan uzun süre devam eden, maksillofasiyal alanda mevcut olan nekrotik kemikle karakterizedir. Osteonekroza, en sık çene kemikleri olmak üzere kalça ve diz kemiklerinde de rastlanmaktadır. MRONJ'ye neden olan ilaçlar, metastaz yapan malignansilerde, osteoporoz ve Paget hastalığının tedavisinde tercih edilmektedir. MRONJ vakalarının patofizyolojisi, henüz tam olarak aydınlatılamamış olmakla birlikte bu durum, kemiğin 'remodeling' mekanizmasının değişmesi veya kemik rezorpsiyonunun baskılanması, enfeksiyon, immün sistem yetmezliği, anjiyogenezin inhibisyonu, yumuşak doku toksisitesi, kronik mikrotravmalar ve D vitamini yetersizliğiyle açıklanabilmektedir. Önerilen cerrahi ve konservatif tedavi rejimlerinin uygulanması değişken başarı oranları sağlamıştır. Semptomatik tedavilerin başarısız kaldığı vakalarda, cerrahi debridman, enfekte dişin çekimi, oluşmuş nekrotik kemiğin rezeksiyonu gibi cerrahi girişimler gerekli olabilir. Cerrahi girişimlerin başarı şansını artırmak için piezocerrahi, lazer cerrahisi, plateletten zengin plazma uygulanması, lökosit ve plateletten zengin fibrin (L-PRF) kullanımı, ozon terapisi gibi yöntemler de ek tedavi olarak uygulanabilmektedir. MRONJ tedavisinde belki de en önemli basamak, risk grubundaki hastaları bilinçlendirmek ve MRONJ oluşumunu önlemektir. Mevcut literatürün en iyi kanıt incelemesine dayanan bu derleme, MRONJ'nin önlenmesi, yönetilmesi ve tedavi edilmesine yardımcı olacak açık pratik kılavuzlar ve yeni tedavi yöntemleri sunmaktadır. MRONJ'ye multidisipliner bir yaklaşım benimsenmeli, hastanın yaşam kalitesi ön planda tutulmalıdır.

Anahtar Kelimeler: Çenenin bifosfonatla ilişkili osteonekrozu; osteonekroz; bifosfonatlar
ABSTRACT
 The first article about medication related osteonecrosis of the jaw (MRONJ) was published in 2003. MRONJ is characterized by exposed necrotic bone in the maxillofacial area that persists for more than eight weeks in patients taking antiresorptive or antiangiogenic drugs for bone metastasis or osteoporosis. Osteonecrosis is most commonly seen in the bones of the jaw, hip and knee. Drugs that cause MRONJ are preferred for the treatment of metastasis malignancies, osteoporosis and Paget disease. Although the pathophysiology of MRONJ cases has not been fully elucidated yet, this may be explained by the alteration of bone remodeling mechanism or suppression of bone resorption, infection, inhibition of angiogenesis, soft tissue toxicity, immune system failure, chronic microtrauma and vitamin D deficiency. The application of the recommended surgical and conservative treatment regimens have returned variable success rates. In cases where symptomatic treatments fail; surgical procedures such as surgical debridement, extraction of infected tooth, resection of the necrotic bone may be necessary. To increase the chances of success of surgical interventions; piezosurgery, laser surgery, platelet rich plasma application, leukocyte and platelet rich fibrin use, ozone therapy can also be applied as additional treatment. This review, based on best evidence review of currently available literature provides clear practical guidelines and new treatment methodes to help to prevent, manage and treat MRONJ. All inclusive, a multidisciplinary approach to MRONJ should be adopted, prioritizing patient's quality of life.

Keywords: Biphosphonate-associated osteonecrosis of the jaw; osteonecrosis; bisphosphonates
REFERENCES:
  1. Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine. 2006;73(5):500-7. [Crossref]  [PubMed] 
  2. Marx RE, Stern D. Oral and Maxillofacial Pathology: a Rationale for Diagnosis and Treatment. 1st ed. Chicago: Quintessence Pub. Co.,; 2003. p.908.
  3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofacial Surg. 2003;61(9):1115-7. [Crossref]  [PubMed] 
  4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56. [Crossref]  [PubMed] 
  5. Duygu Çapar G, Cabbar F, Yalçın GM, Özçakır Tomruk C. [Medication related jaw osteonecrosis: review]. J Dent Fac Atatürk Uni. 2015; Suppl 13;118-29.
  6. Henien M, Carey B, Hullah E, Sproat C, Patel V. Methotrexate-associated osteonecrosis of the jaw: a report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124(6):e283-e7. [Crossref]  [PubMed] 
  7. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567-75. [Crossref]  [PubMed] 
  8. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65. [Crossref]  [PubMed] 
  9. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694-701. [Crossref]  [PubMed]  [PMC] 
  10. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;5;377(9768):813-22. [Crossref] 
  11. Stopeck A, Body JJ, Fujiwara Y, Lipton A. 2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. EJC Supplements. 2009;7(3):2-3. [Crossref] 
  12. Baron R, Ferrari S, Graham R, Russell G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;1;48(4):677-92. [Crossref]  [PubMed] 
  13. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;15;12(20 Pt 2):6222s-30s. [Crossref]  [PubMed] 
  14. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25(1):97-106. [Crossref]  [PubMed] 
  15. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527-34. [Crossref]  [PubMed] 
  16. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23(6):826-36. [Crossref]  [PubMed]  [PMC] 
  17. Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137-45. [Crossref]  [PubMed] 
  18. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41(3):318-20. [Crossref]  [PubMed] 
  19. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12(3 Suppl):233-47. [Crossref] 
  20. Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 2010;177(1):280-90. [Crossref]  [PubMed]  [PMC] 
  21. Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, et al. Increased prevalence of bisphosphonate‐related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res. 2010;25(6):1337-49. [Crossref]  [PubMed]  [PMC] 
  22. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(4):433-41. [Crossref]  [PubMed] 
  23. Wood J, Bonjean K, Ruetz S, Bellahcéne A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055-61. [Crossref]  [PubMed] 
  24. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32(11):1123-8. [Crossref]  [PubMed] 
  25. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;1;21(21):4042-57. [Crossref]  [PubMed] 
  26. Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, et al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw‐like lesions in rice rats (oryzomys palustris) with periodontitis. J Bone Miner Res. 2012;27(10):2130-43. [Crossref]  [PubMed]  [PMC] 
  27. Kang B, Cheong S, Chaichanasakul T, Bezouglaia O, Atti E, Dry SM, et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res. 2013;28(7):1631-40. [Crossref]  [PubMed]  [PMC] 
  28. Hansen T, Kunkel M, Weber A, Kirkpatrick CJ. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35(3):155-60. [Crossref]  [PubMed] 
  29. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75-85. [Crossref]  [PubMed] 
  30. McGowan K, McGowan T, Ivanovski S. Risk factors for medication‐related osteonecrosis of the jaws: a systematic review. Oral Dis. 2018;24(4):527-36. [Crossref]  [PubMed] 
  31. Otto S, Schuler K, Ihrler S, Ehrenfeld M, Mast G. Osteonecrosis or metastases of the jaw or both? Case report and review of the literature.J Oral Maxillofac Surg. 2010;68(5):1185-8. [Crossref]  [PubMed] 
  32. Otto S, Hafner S, Grötz KA. The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2009;67(3):589-92. [Crossref]  [PubMed] 
  33. Yalcin ED, Gungormus M. Cone-beam computed tomography ımaging findings of bisphosphonate-related osteonecrosis of the Jaws (BRONJ): a review article. Int J Dent Sci Res. 2015;3(5):111-5.
  34. Boeddinghaus R, Whyte A. Trends in maxillofacial imaging. Clin Radiol. 2018;73(1):4-18. [Crossref]  [PubMed] 
  35. Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, et al. Evaluation of the treatment strategies for medication‐related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res. 2017;32(10):2022-29. [Crossref]  [PubMed] 
  36. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment. 2nd ed. Chicago, Ill, USA: Quintessence; 2007. p.160.
  37. Yildiz A, Esen E, Kürkçü M, Damlar I, Dağlioğlu K, Akova T, et al. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model. J Oral Maxillofac Surg. 2010;68(3):515-23. [Crossref]  [PubMed] 
  38. Abtahi J, Tengvall P, Aspenberg P. Bisphosphonate coating might improve fixation of dental implants in the maxilla: a pilot study. 2010;39(7): 673-7. [Crossref]  [PubMed] 
  39. Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. 2012;50(5):1148-51. [Crossref]  [PubMed] 
  40. Ristow O, Rückscloß T, Müller M, Berger M, Kargus S, Pautke C, et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg. 2019;47(3):491-9. [Crossref]  [PubMed] 
  41. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28(4):365-83. [Crossref]  [PubMed] 
  42. Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2015;43(2):290-3. [Crossref]  [PubMed] 
  43. Merigo E, Cella L, Aldo Oppici, Arbasi MC, Clini F, Fontana M, et al. Combined approach to treat medication-related osteonecrosis of the jaws. J Lasers Med Sci. 2018;9(2):92-100. [Crossref]  [PubMed]  [PMC] 
  44. Blus C, Szmukler-Moncler S, Giannelli G, Denotti G, Orrù G. et al. Use of ultrasonic bone surgery (Piezosurgery) to surgically treat bisphosphonate-related osteonecrosis of the jaws (BRONJ). A case series report with at least 1 year of follow-up. Open Dent J. 2013;23;7:94-101. [Crossref]  [PubMed]  [PMC] 
  45. escovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S, et al. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent. 2014;2014:107690. [Crossref]  [PubMed]  [PMC] 
  46. Vescovi P, Giovannacci I, Otto S, Manfredi M, Merigo E, Fornaini C, et al. Medication-related osteonecrosis of the jaw: an autofluorescence-guided surgical approach performed with er: YAG laser. Photomed Laser Surg. 2015;33(8):437-42. [Crossref]  [PubMed] 
  47. Atalay B, Yalcin S, Emes Y, Aktas I, Aybar B, Issever H, et al. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers Med Sci. 2011;26(6):815-23. [Crossref]  [PubMed] 
  48. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc. 2007;138(7):971-7. [Crossref]  [PubMed] 
  49. Cano-Durán JA, Pe-a-Cardelles JF, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, López-Quiles J, et al. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017;1;9(8):e1051-e9. [PubMed] 
  50. Owosho AA, Estilo CL, Huryn JM, Yom SHK. et al. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(4):455-9. [Crossref]  [PubMed]  [PMC] 
  51. Keskinrüzgar A, Yanık S, Aras MH, Çetiner S. [Teriparatide [parathyroid hormone (1-34)] and dentistry]. Acta Odontol Turc. 2015;32(3):165-70. [Crossref] 
  52. Dyas A, Boughton BJ, Das BC. Ozone killing action against bacterial and fungal species; microbiological testing of a domestic ozone generator. J Clin Pathol. 1983;36(10):1102-4. [Crossref]  [PubMed]  [PMC] 
  53. Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int. 2016;2016:8768162. [Crossref]  [PubMed]  [PMC] 
  54. Agrillo A, Filiaci F, Ramieri V, Riccardi E, Quarato D, Rinna C, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci. 2012;16(12):1741-7. [PubMed] 
  55. Vescovi P, Manfredi M, Merigo E. Adjuvant treatment options in the management of medication-related osteonecrosis of the jaw. Medication-Related Osteonecrosis of the Jaws. 2015. p.103-9. [Crossref] 
  56. Rugani P, Acham S, Kirnbauer B, Truschnegg A, Obermayer-Pietsch B, Jakse N. et al. Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series. Clin Oral Investig. 2015;19(6):1329-38. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com